An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD) (LAMP)
An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration
Sponsor: Chengdu Kanghong Biotech Co., Ltd.
A PHASE2 clinical study on Very Low Vision Secondary to Wet Age-related Macular Degeneration, this trial is ongoing. The trial is conducted by Chengdu Kanghong Biotech Co., Ltd. and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chengdu Kanghong Biotech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .